Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2015

01-09-2015 | Research Article

Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma

Authors: Chun-Xiao Zhang, Long-Wei Ye, Ying Liu, Xiao-Ya Xu, Dan-Rui Li, Yan-Qing Yang, Lu-Lu Sun, Jie Yuan

Published in: Tumor Biology | Issue 9/2015

Login to get access

Abstract

Newcastle disease virus (NDV), an avian paramyxovirus, possesses the ability to kill tumor cells. Here, we report the effects of NDV strain D90, which was isolated in China, against oral squamous cell carcinoma (OSCC) cells. In this study, we showed that the cell death induced by D90 was apoptotic. Furthermore, the apoptosis induced by D90 was dependent on the mitochondrial pathway, and the death receptor pathway may be not involved. Bax and Bcl-2 also played a role in the apoptosis induced by D90. Lymph node metastasis is a serious problem for oral cancer; we therefore evaluated the impact of D90 on the migration and invasion of OSCC cells. NDV D90 affected microtubules and microfilaments to inhibit the motility of OSCC prior to apoptosis. The effects of D90 on the migration and invasion rates of OSCC cells were evaluated by migration and invasion assays. Subsequently, the changes in sp1, RECK, MMP-2, and MMP-9 induced by a low concentration of D90 were detected by western blot and gelatin zymography. D90 significantly inhibited the invasion and metastasis of OSCC cells by decreasing the expression of sp1 and increasing the expression of RECK to suppress the expression and activity of MMP-2 and MMP-9.
Literature
1.
Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–16.CrossRefPubMed
2.
3.
Lam HY, Yeap SK, Rasoli M, et al. Safety and clinical usage of Newcastle disease virus in cancer therapy. J Biomed Biotechnol. 2011. doi:10.​1155/​2011/​718710.
4.
5.
Romer-Oberdorfer A, Werner O, Veits J, Mebatsion T, Mettenleiter TC. Contribution of the length of the HN protein and the sequence of the F protein cleavage site to Newcastle disease virus pathogenicity. J Gen Virol. 2003;84:3121–9.CrossRefPubMed
6.
Ravindra PV, Tiwari AK, Sharma B, Chauhan RS. Newcastle disease virus as an oncolytic agent. Indian J Med Res. 2009;130(5):507–13.PubMed
7.
8.
Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol. 2006;80(15):7522–34.CrossRefPubMedPubMedCentral
9.
Laurie SA, Bell JC, Atkins HL, et al. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res. 2006;12:2555–62.CrossRefPubMed
10.
Alabsi AM, Ali R, et al. Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo. Leuk Res. 2012;36(5):634–45.CrossRefPubMed
11.
Jamal MH, Ch’ng WC, Yusoff K, Shafee N. Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization. Cancer Cell Int. 2012;12(1):35.CrossRefPubMedPubMedCentral
12.
Meng C, Zhou Z, Jiang K, et al. Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. Arch Virol. 2012;157(6):1011–8.CrossRefPubMed
13.
Lazar L, Yaacov B, Shiloach T, et al. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J Virol. 2010;84(1):639–46.CrossRefPubMed
14.
Bian J, Wang K, Kong X, et al. Caspase-and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus. Arch Virol. 2011;156(8):1335–44.CrossRefPubMed
15.
Csatary K, Gosztonyi G, Szeberenyi J, et al. MTH-68/H oncolytic vital treatment in human high-grade gliomas. J Neurooncol. 2004;67(1–2):83–93.CrossRefPubMed
16.
Freeman AL, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2006;13(1):221–8.CrossRefPubMed
17.
Hotte SJ, Lorence RM, Hirte HW, et al. An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res. 2007;13(3):977–85.CrossRefPubMed
18.
Reichard KW, Lorence RM, Cascino CJ, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res. 1992;52(5):448–53.CrossRefPubMed
19.
Alabsi AM, Bakar SA, Ali R, et al. Effects of Newcastle disease virus strains AF2240 and V4-UPM on cytolysis and apoptosis of leukemia cell lines. Int J Mol Sci. 2011;12(12):8645–60.CrossRefPubMedPubMedCentral
20.
Zamarin D, Viqil A, Kelly K, Garcia-Sastre A, Fong Y. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 2009;16(6):796–804.CrossRefPubMedPubMedCentral
21.
Viqil A, Park MS, Martinez O, et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 2007;67(17):8285–92.CrossRef
22.
Biswas M, Kumar SR, Allen A, et al. Cell-type-specific innate immune response to oncolytic Newcastle disease virus. Viral Immunol. 2012;25(4):268–74.CrossRefPubMedPubMedCentral
23.
Molouki A, Yusoff K. NDV-induced apoptosis in absence of Bax; evidence of involvement of apoptotic proteins upstream of mitochondria. Virol J. 2012;9:179.CrossRefPubMedPubMedCentral
24.
Sui H, Bai Y, Wang K, et al. The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting. Cancer Immunol Immunother. 2010;59(7):989–99.CrossRefPubMed
25.
Woolqar JA, Scott J, Vauqhan ED, et al. Survival, metastasis and recurrence of oral cancer in relation to pathological features. Ann R Coll Surg Engl. 1995;77(5):325–31.
26.
Kato K, Long NK, Makita H, et al. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br J Cancer. 2008;99(4):647–54.CrossRefPubMedPubMedCentral
27.
Hsu MC, Chang HC, Hung WC. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem. 2006;281(8):4718–25.CrossRefPubMed
28.
Puff C, Krudewiq C, Imbschweiler L, Baumqártner W, Alldinqer S. Influence of persistent canine distemper virus infection on expression of RECK, matrix-metalloproteinases and their inhibitors in a canine macrophage/monocytic tumour cell line (DH82). Vet J. 2009;182(1):100–7.CrossRefPubMed
29.
Tswnq MY, Liu SY, Chen HR, et al. Serine protease inhibitor (SERPIN) B1 promotes oral cancer motility over-expressed in invasive oral squamous cell carcinoma. Oral Oncol. 2009;45(9):771–6.CrossRef
30.
Kumar R, Tiwari AK, Chaturvedi U, et al. Velogenic Newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization. Appl Biochem Biotechnol. 2012;167(7):2005–22.CrossRefPubMed
31.
Wu Y, Zhang X, Wang X, et al. Apoptin enhance the oncolytic properties of Newcastle disease virus. Intervirology. 2012;55(4):276–86.CrossRefPubMed
32.
Li P, Chen CH, Li S, et al. Therapeutic effects of a fusogenic Newcastle disease virus in treating head and neck cancer. Head Neck. 2011;33(10):1394–9.CrossRefPubMed
33.
Silberhumer GR, Brader P, Wong J, et al. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther. 2010;9(10):2761–9.CrossRefPubMedPubMedCentral
34.
Song KY, Wong J, Gonzalez L, et al. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. J Mol Med (Berl). 2010;88(6):589–96.CrossRef
35.
Fu F, Zhao M, Yang YJ, et al. Antiproliferative effect of Newcastle disease virus strain D90 on human lung cancer line A549. Oncol Res. 2011;19(7):323–33.CrossRefPubMed
36.
Washburn B, Weiqand MA, Grosse-Wilde A, et al. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol. 2003;170(4):1814–21.CrossRefPubMed
37.
Fábián Z, Csatary CM, Szeberényi J, Csatary LK. P53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol. 2007;81(6):2817–30.CrossRefPubMedPubMedCentral
38.
Marek Ł. The role of the apoptosome in the activation of procaspase-9. Postepy Hig Med Dosw (Online). 2013;67:54–64.CrossRef
39.
Salvesen GS. Caspases and apoptosis. Biochemistry. 2002;38:9–19.
40.
Molouki A, Hsu YT, Jahanshiri F, Rosli R, Yusoff K. Newcastle disease virus infection promotes Bax redistribution to mitochondria and cell death in HeLa cells. Intervirology. 2010;53(2):87–94.CrossRefPubMed
41.
Ravindra PV, Tiwari AK, Ratta B, et al. Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosis. Virus Res. 2009;141(1):13–20.CrossRefPubMed
Metadata
Title
Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma
Authors
Chun-Xiao Zhang
Long-Wei Ye
Ying Liu
Xiao-Ya Xu
Dan-Rui Li
Yan-Qing Yang
Lu-Lu Sun
Jie Yuan
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3433-z

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue

Research Article

ObRb downregulation increases breast cancer cell sensitivity to tamoxifen

Research Article

Gender and plasma iron biomarkers, but not HFE gene mutations, increase the risk of colorectal cancer and polyps

Research Article

MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK

Research Article

A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer

Retraction Note

Retraction Note to: Identification of core miRNA based on small RNA-seq and RNA-seq for colorectal cancer by bioinformatics

Retraction Note

Retraction Note to: Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits